P-198 - Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anticancer agents
Colon and Rectal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter M. Schirripa
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors M. Schirripa1, A. Falcone2, F. Loupakis1, C. Cremolini1, L. Poliseno3, L. Salvatore1, A. Tuccoli1, C. Antoniotti1, R. D'Aurzio1, F. Marmorino1, B. Borelli4, D. Rossini1, A. Saettini1, S. Gini1, R. Moretto5, I. Rizzo1, E. Dell' Aquila4, M. Pellegrini1
  • 1Istituto Toscano Tumori, Pisa/IT
  • 2University of Pisa, Pisa/IT
  • 3IFC-CNR, Pisa/IT
  • 4Azienda Ospedaliero Universitaria Pisana, Pisa/IT
  • 5Azienda Ospedaliero-Universitaria Pisana, Pisa/IT



Regorafenib is indicated for the treatment of mCRC patients who have failed all other therapies. Nevertheless a substantial percentage of patients experiences rapid disease progression (PD) and serious adverse events may occur. For these reasons, clinical and/or molecular markers able to improve the cost/benefit ratio are urgently needed. Circulating microRNAs (c-miRNAs) have been recognized as possible prognostic and diagnostic markers in mCRC. The aim of this study was to describe the early changes in plasma levels of 10 selected c-miRNAs during the treatment with regorafenib and to investigate their correlation with clinical outcome.


Plasma samples of patients treated with regorafenib at our Institution were collected at baseline (D1) and after 15 days of treatment (D15). Plasma levels of c-miR-17, c-miR-21, c-miR-29, c-miR-34, c-miR-92, c-miR-126, c-miR-141, c-miR-221, c-miR-601, c-miR-760 were analysed by means of real-time PCR. Paired levels at D1 and D15 were compared by means of Wilcoxon test for each c-miRNA. C-miRNAs showing significant changes were further analysed in order to identify possible correlations with outcome.


Thirty-four patients were included in the present study. Main characteristics were the following: M/F = 50%/50%; median age = 65 (range 48-78 years); ECOG-PS 0/1-2 = 71%/29%; time from diagnosis of metastases


The early modulation of c-miR-21 levels may predict benefit from regorafenib in terms of disease control. These results need validation in independent series.